VERTIPRESS
Brand:
VERTIPRESS
Manufacturer:
CIPLA
Manufacturer Details
CIPLA
Compositions:
Betahistine 8mg/16mg/24mg/32mg tablets,
|
Strength
|
Rate
|
Packing Style
|
|
8mg
|
62.31
|
10s tablets
|
|
16mg
|
142.41
|
10s tablets
|
|
24mg
|
194.20
|
10s tablets
|
|
32mg
|
110.00
|
10s tabs
|
List of Related Indications:
List Of Drugs:
- Betahistine - @ Antivertigo drugs
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
May antagonise antihistamines. No significant drug interactions have been reported
Indication:
Menieres syndrome Vertigo, Tinnitus
New drugs approved For Marketing by Drug Controller General of India(DCGI )
during the period January 1988 to November 2014
(Ref- IDMA Annual Publication 2015)
Name of Drug Indication Date of Approval
1.Betahistine dihydrochloride CR caps 17-12-2009
24/32/48mg
Indicated in the treatment of meniers syndrome characterized by
unilateral or bilateral tinnitus , vertigo, sensorineural hearing
loss
2.Betahistine dihydrochlorise SR tablets 14-03-2013
24mg/32mg/48mg
For the symptomatic treatment of peripheral vertigo
3. Betahistine 0.05% + Miconazole 2% cream 12-03-2008
For the treatment of dizziness and feeling resulting from
Mineres disease , menieres syndrome and vertigo
Adverse Reaction:
Mild skin and GI disturbances.
Ocassionally,headache, dizziness,insomnia. Nausea, dyspepsia, headaches, drowsiness, Abdominal cramps, dizziness
Contra-Indications:
Phaeochromocytoma.Neonates.
Contraindicated in bronchial asthma, peptic ulceration, urticaria and rhinitis
Special precautions:
Active peptic ulcer,bronchial asthma,pregnancy
Betahistine is excreted in the milk of nursing mothers in concentrations similar to that found in plasma. Not recommended for children and neonates.
Dosages/ Overdosage Etc:
Indication-
Menieres syndrome,
Vertigo, Tinnitus
Dosage-
Oral : 8mg to 16mg three times a day. after meals
Maintenance - up to 24-48mg daily
Patient Information:
Not recommended during pregnancy and nursing woman.
Not recommended for children and neonates
Pharmacology/ Pharmacokinetics:
Pharmacology:
Molecular structure and pharmacoilogical actions of betahistine is similar to that of histamine, although its pharmacological actions are less potent than that of histamine.
Pharmacokinetics:
Following oral administration, betahistine is completely absorbed and peak plasma concentrations reached after 1 hour. Elimination studies show that 85- 90% of betahistine is eliminated in urine over 56 hours.Little or no binding of betahistine to either serum albumin or other plasma proteins have been reported.
Interaction with Food:
Tablets to be taken after meals
Pregnancy and lactation:
Not recommended for use during pregnancy and lactation.
Not recommended for use on children and neonates.
